PCM
FLNA

Palisade Capital Management’s Filana Therapeutics FLNA Stock Holding History

Palisade Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-21,429
Closed -$586K – 496
2014
Q3 		$586K Buy
21,429
+7,143
+50% +$217K 0.01% 415
2014
Q2 		$575K Buy
14,286
+2,857
+25% +$106K 0.01% 411
2014
Q1 		$440K Buy
11,429
+4,286
+60% +$151K 0.01% 418
2013
Q4 		$243K Buy
7,143
+1,429
+25% +$37.9K 0.01% 422
2013
Q3 		$109K Buy
+5,714
New +$99.9K ﹤0.01% 438

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Palisade Capital Management's FLNA Position: Q4 2014 in Review

Palisade Capital Management sold out of Filana Therapeutics (FLNA) in Q4 2014, closing a stake of 21,429 shares — an estimated $586K sold.

Palisade Capital Management first reported a position in FLNA in Q3 2013 and held it in 5 quarters. The position peaked at $586K in Q3 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q4 2014.

  • Palisade Capital Management reported no remaining Filana Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Palisade Capital Management sold 21,429 Filana Therapeutics shares in Q4 2014, an estimated $586K.
  • Palisade Capital Management first reported a position in Filana Therapeutics in Q3 2013 and held it in 5 quarters.
  • Palisade Capital Management's Filana Therapeutics position peaked at $586K in Q3 2014.
  • 66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2014.

Based on Palisade Capital Management's 13F filing for Q4 2014, filed 11 Feb 2015.